{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:52:03Z","timestamp":1790664723663,"version":"4.1.0"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2005]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>In order to elucidate the role of VCORC1 sequence variants in warfarin sensitivity, we established a complete SNP map of the VKORC1 gene locus in 200 blood donors from Western Germany. Nearly all of the genetic variability of the VKORC1 gene in Europeans is reflected by three main haplotypes. Recently described polymorphisms associated with low warfarin dose requirement (dbSNP:rs9934438; dbSNP:rs17878363) were found in complete linkage disequilibrium with the VKORC1*2 haplotype. In two patient cohorts of European origin with either increased coumarin sensitivity (n=14) or partial coumarin resistance (n=36) the VKORC1*2 frequency varied highly significant between the two groups and also when compared to 200 blood donor controls (coumarin sensitive 96%, coumarin resistant 7%, controls 42%) thus demonstrating a strong association between these two phenotypes and the VKORC1 haplotype (p = 1.6 x 10\u22128 for coumarin sensitive and p = 1.9 x 10\u22128 for coumarin resistant). Analysis of database derived VKORC1 genotypes of African Americans and Chinese revealed that haplotype frequencies in these populations differ significantly from the European sample (for VKORC1*2: Europeans 42%, Chinese 95%, African Americans 14%). These observations suggest VKORC1 as principal genetic modulator of the ethnic differences in warfarin response. Since hereditary pharmacodynamic (VKORC1) and pharmacokinetic (CYP2C9) factors account for up to 50% of the inter-individual variability of the warfarin response, these genetic markers may serve as clinically relevant predictors of warfarin dosing in future studies.<\/jats:p>","DOI":"10.1160\/th05-04-0290","type":"journal-article","created":{"date-parts":[[2005,9,10]],"date-time":"2005-09-10T15:47:53Z","timestamp":1126367273000},"page":"773-779","source":"Crossref","is-referenced-by-count":197,"title":["VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation"],"prefix":"10.1160","volume":"94","author":[{"given":"Christof","family":"Geisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Watzka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Sittinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Steffens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurynas","family":"Daugela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhard","family":"Seifried","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens R.","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Wienker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,12,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature02214","article-title":"Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2","volume":"427","author":"S Rost","year":"2004","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature02254","article-title":"Identification of the gene for vitamin K epoxide reductase","volume":"427","author":"T Li","year":"2004","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"10540","DOI":"10.1074\/jbc.M413982200","article-title":"Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system","volume":"280","author":"N Wajih","year":"2005","journal-title":"J Biol Chem"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/j.1538-7836.2004.00968.x","article-title":"The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis","volume":"2","author":"KL Berkner","year":"2004","journal-title":"J Thromb Haemost"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1160\/TH04-08-0540","article-title":"Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1","volume":"93","author":"DJ Harrington","year":"2005","journal-title":"Thromb Haemost"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1534\/genetics.104.040360","article-title":"The genetic basis of resistance to anticoagulants in rodents","volume":"170","author":"HJ Pelz","year":"2005","journal-title":"Genetics"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2004-06-2111","article-title":"A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin","volume":"105","author":"G D\u2019Andrea","year":"2005","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/jcp.45.8.704","article-title":"Factors affecting the maintenance dose of warfarin","volume":"45","author":"AH James","year":"1992","journal-title":"J Clin Pathol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1160\/TH03-06-0379","article-title":"Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin","volume":"91","author":"BF Gage","year":"2004","journal-title":"Thromb Haemost"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0002-9343(00)00545-3","article-title":"Management and dosing of warfarin therapy","volume":"109","author":"BF Gage","year":"2000","journal-title":"Am J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.0954-6820.1972.tb04800.x","article-title":"Determinants of the response to coumarin anticoagulants in patients with acute myocardial infarction","volume":"192","author":"P Ristola","year":"1972","journal-title":"Acta Med Scand"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/003693308703200604","article-title":"A flexible loading dose schedule for warfarin therapy","volume":"32","author":"RJ Fergusson","year":"1987","journal-title":"Scott Med J"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1345\/aph.1C025","article-title":"Patient-specific factors predictive of warfarin dosage requirements","volume":"36","author":"RK Absher","year":"2002","journal-title":"Ann Pharmacother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0037-1614485","article-title":"Vitamin K intake and sensitivity to warfarin in patients consuming regular diets","volume":"81","author":"A Lubetsky","year":"1999","journal-title":"Thromb Haemost"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1365-2141.2001.02635.x","article-title":"The association of vitamin K status with warfarin sensitivity at the onset of treatment","volume":"112","author":"M Cushman","year":"2001","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood.V96.5.1816","article-title":"Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment","volume":"96","author":"J Taube","year":"2000","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1160\/TH03-12-0741","article-title":"The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon","volume":"92","author":"LE Visser","year":"2004","journal-title":"Thromb Haemost"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.clpt.2004.01.008","article-title":"Pharmacogenetics of acenocoumarol pharmacodynamics","volume":"75","author":"S Morin","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nature02168","article-title":"HapMap Project","volume":"426","author":"International The","year":"2003","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/sj.ejhg.5201164","article-title":"Detection of genotyping errors by Hardy-Weinberg equilibrium testing","volume":"12","author":"L Hosking","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1006\/geno.1995.9003","article-title":"A comparison of linkage disequilibrium measures for fine-scale mapping","volume":"29","author":"B Devlin","year":"1995","journal-title":"Genomics"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000022901","article-title":"Model-free analysis and permutation tests for allelic associations","volume":"50","author":"JH Zhao","year":"2000","journal-title":"Hum Hered"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/424390","article-title":"A powerful strategy to account for multiple testing in the context of haplotype analysis","volume":"75","author":"T Becker","year":"2004","journal-title":"Am J Hum Genet"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/blood-2005-01-0341","article-title":"Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity","volume":"106","author":"L Bodin","year":"2005","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/hmg\/ddi180","article-title":"A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity","volume":"14","author":"HY Yuan","year":"2005","journal-title":"Hum Mol Genet"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.tpj.6500313","article-title":"Common VKORC1 and GGCX polymorphisms associated with warfarin dose","volume":"5","author":"M Wadelius","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":"Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose","volume":"352","author":"MJ Rieder","year":"2005","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"15045","DOI":"10.1021\/bi026016e","article-title":"Carboxylase overexpression effects full carboxylation but poor release and secretion of factor IX: implications for the release of vitamin K-dependent proteins","volume":"41","author":"KW Hallgren","year":"2002","journal-title":"Biochemistry"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/BF02983247","article-title":"Racial background is a determinant factor in the maintenance dosage of warfarin","volume":"78","author":"GG Gan","year":"2003","journal-title":"Int J Hematol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1532\/IJH97.A20401","article-title":"Genetic polymorphism of the CYP2C9 subfamily of 3 different races in warfarin maintenance dose","volume":"80","author":"GG Gan","year":"2004","journal-title":"Int J Hematol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clpt.2004.05.005","article-title":"Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose","volume":"76","author":"F Zhao","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy","volume":"348","author":"G Palareti","year":"1996","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-0037-1614114","article-title":"Genetic modulation of oral anticoagulation with warfarin","volume":"84","author":"M Margaglione","year":"2000","journal-title":"Thromb Haemost"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1160\/TH04-02-0083","article-title":"Warfarin dosing and cytochrome P450 2C9 polymorphisms","volume":"91","author":"HV Joffe","year":"2004","journal-title":"Thromb Haemost"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1055\/s-2003-44458","article-title":"Genetic regulation of warfarin metabolism and response","volume":"3","author":"AK Daly","year":"2003","journal-title":"Semin Vasc Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications","volume":"353","author":"GP Aithal","year":"1999","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy","volume":"287","author":"MK Higashi","year":"2002","journal-title":"JAMA"},{"key":"ref38","first-page":"1185","article-title":"Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation","volume":"87","author":"D Tassies","year":"2002","journal-title":"Haematologica"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH05-04-0290.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T11:53:11Z","timestamp":1685533991000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH05-04-0290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,12,11]]},"published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1160\/th05-04-0290","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005]]}}}